RxDoctor Payments DataLook up a doctor →

Frances Broyles

Endocrinology, Diabetes & Metabolism · Seattle, WANPI 1669454583

Payments from drug & device makers

$5,646,764in general payments, 2019–2025

Across 537 payments — averaging $10,515 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$2.9M
  • Abbott$836K
  • Boehringer Ingelheim$567K
  • AbbVie$520K
  • Xeris Pharmaceuticals, Inc.$209K
  • Roche Diabetes Care, Inc.$201K
  • plus $433K from 12 others
$34,077in research payments, 2019–2025

Across 26 payments — averaging $1310.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$33K
  • AbbVie$1K

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,646,764 in reported general payments places this provider in the 95th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.

See all endocrinology, diabetes & metabolism providers in Washington

Other endocrinology, diabetes & metabolism in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →